The Phase 3 entry covering children and adolescents was last updated on 30 September 2026 and carries the status recruiting.
Bethesda, Maryland, 30 September 2026 — The ClinicalTrials.gov registry record with identifier NCT07253285, a Phase 3 interventional study sponsored by Novo Nordisk A/S, was last updated on 30 September 2026. The overall status on the record is recruiting, and the registered brief title describes children and adolescents as the registered population.
Source documents
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Identifier
- Registry identifier NCT07253285
- Registry status
- RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-09-30